UK Chronic Lymphocytic Leukaemia (CLL) Forum
@UkCllforum
Followers
1K
Following
65
Media
141
Statuses
336
A UK group of physicians and patients committed to improve #CLL care and providing education about CLL in the UK https://t.co/f9g7JsLB6y
Joined September 2019
Announcing our 2026 "Complete CLL Course: From basics to latest updates in the management of people with CLL" SAVE THE DATE! and join us for 3 evenings of full immersion in CLL. Agenda below. Registration link will come out shortly
0
0
0
Dr Renata Walewska wrapped up the clinical sciences day with a review of the new BSH guidelines for treatment of #CLL. Great end to a fruitful meeting. Next stop our CLL basic course in January 2026. Thanks to organisers and meeting chairs.
0
0
1
Dr Moritz Fürstenau give his perspective and on triple therapy for #CLL. Emerging data from CLL13 Clear signal of increased toxicity of triplet GIV, worse QoL and higher symptom burden. Jury’s out if these findings justify better efficacy in uIGHV. Longer FUP needed.
0
0
1
Congratulations to Dr Jin, winner of the Hamlin price with his work on PROTACS to target NFkB pathway in #CLL. Excellent output from the UK CLL scientific community.
0
0
0
Live from central London- @UkCllforum clinical sciences day is underway. Dr Munir is providing us an update of the FLAIR trial latest results. MRD guided I+V is the new benchmark for CLL 1L therapy, showing OS advantage for the first time in a decade.
0
0
0
Live from central London- @UkCllforum clinical sciences day is underway. Dr Munir is providing us an update of the FLAIR trial latest results. MRD guided I+V is the new benchmark for CLL 1L therapy, showing OS advantage for the first time in a decade.
0
1
0
Live from central London- @UkCllforum clinical sciences day is underway. Dr Munir is providing us an update of the FLAIR trial latest results. MRD guided I+V is the new benchmark for CLL 1L therapy, showing OS advantage for the first time in a decade.
0
1
0
Few days to go for the @UkCllforum annual clinical sciences day. Still time to register. Followers- spread the voice! 📣📣 Link to program and registration👇 https://t.co/Yg2bgyl2mN Keynote talks from Dr Siddiqi and Dr Fürstenau.
0
0
1
Few days to go for the @UkCllforum annual clinical sciences day. Still time to register. Followers- spread the voice! 📣📣 Link to program and registration👇 https://t.co/Yg2bgyl2mN Keynote talks from Dr Siddiqi and Dr Fürstenau.
0
1
0
Few days to go for the @UkCllforum annual clinical sciences day. Still time to register. Followers- spread the voice! 📣📣 Link to program and registration👇 https://t.co/Yg2bgyl2mN Keynote talks from Dr Siddiqi and Dr Fürstenau.
0
1
0
🚨Followers. @UkCllforum clinical science day is fast approaching. 3rd of October 2025 at the Cavendish conference centre-London. Featuring parallel CLL nurse forum meeting in collaboration with @LeukaemiaCareUK Still time to register!
0
0
0
🎙️ The first episode of our #BloodCancerAwarenessMonth podcast special is here! Experts answer YOUR questions on #CLL, #myeloma & #lymphoma 🔬✨ Featuring Barbara Eichhorst, @DrRakeshPopat & @AnnaSureda5. 👉 Listen now: https://t.co/e3Y0wZ1D82 Stay tuned for next week’s
0
2
4
Thank you to @DrMDavids (@DanaFarber) for catching up with us today at #iwCLL2025!😁 We heard about: 👉 the SOUNDTRACK-E & MAVRiC trials 👉 a tandem CD19/ROR1 CAR-NK in CLL 👉 the recently published consensus report on monoclonal B-cell lymphocytosis You won't want to miss this
1
1
2
🎥 Earlier today, @KerryARogersMD of @OSUHematology provided valuable insight into her talk at #iwCLL2025 on targeting surface antigens in CLL. Dr Rogers also discussed the management of double-refractory disease.🩸 Keep an eye out on our site for the full interview soon!
0
4
6
We've just kicked off our second day at #iwCLL2025!🩸😁 It was great to hear from @ChrisPepper64 of @BSMSMedSchool, who shared insight into the development of novel strategies targeting the NF-κB signaling pathway in CLL, including a first-in-class PROTAC. #CLLsm #Leusm
1
1
3
It was a pleasure to catch up with Talha Munir (@LeedsHospitals), who discussed several of his interesting posters at #iwCLL2025. Don't miss the full interview to hear about: 🩸the PhIII STATIC trial 🩸a report of the FLAIR trial 🩸an MAIC of zanu vs fixed-duration AV for 1L CLL
0
1
5
The wonderful Barbara Eichhorst of @UniCologne stopped by to share the 2-year follow-up results from the Phase Ib/II EPCORE CLL-1 trial, and to discuss the frontline treatment of CLL.🩸 Catch this interview, and many more from #iwCLL2025, on https://t.co/O9p0vDBrzw soon!🎥
0
1
4
Watch our insightful interview from #iwCLL2025, in which Alexey Danilov (@DanilovLab) of @cityofhope discusses the emerging promise of targeted protein degraders in CLL and other heme malignancies: 👉 https://t.co/xEh6RXbDiU 👈 #CLLsm #Leusm #Leukemia #HemOnc
vjhemonc.com
Alexey Danilov, MD, PhD, City of Hope, Duarte, CA, comments on the emerging promise of targeted protein degraders in oncology, highlighting their potential to overcome resistance to existing therap...
1
2
1
#iwCLL2025 in Kraków, Poland, is a few weeks away! Engage with cutting-edge insights, collaborate to advance patient management, and foster connections that fuel progress in the field. Sign up today: https://t.co/Ds1v2ntsjE
0
2
5
Colleagues from @lymphomahub have published the top #EHA25 abstracts. FLAIR in the spotlight, alongside final analysis of CLL13 trial. Great read if you have missed EHA. EHA 2025 | Top abstracts in Lymphoma and CLL #CLL
1
0
3